Larimar Therapeutics, Inc.
Clinical-stage biotech developing protein therapies for rare diseases like Friedreich's ataxia.
LRMR | NDAQ
Overview
Corporate Details
- ISIN(s):
- US98885E1038 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- THREE BALA PLAZA EAST. SUITE 506, 19004 BALA CYNWYD
- Website:
- https://larimartx.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's proprietary intracellular delivery platform is designed to transport therapeutic proteins into cells to address diseases caused by protein deficiencies. Its lead product candidate, nomlabofusp (formerly CTI-1601), is being evaluated in a Phase 2 clinical program as a potential therapy for Friedreich's ataxia, a rare and progressive genetic disease. Larimar plans to leverage its technology to create additional fusion protein treatments for other rare conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Larimar Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Larimar Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Larimar Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
